Immunologic predictors of liver transplantation outcomes in HIV-HCV co-infected persons

Ashwin Balagopal, Burc Barin, Jeffrey Quinn, Rodney Rogers, Mark Sulkowski, Peter G. Stock

Research output: Contribution to journalArticle

Abstract

Liver disease is a leading cause of mortality among HIV-infected persons in the highly active anti-retroviral therapy (HAART) era. Hepatitis C Virus (HCV) co-infection is prevalent in, and worsened by HIV; consequently many co-infected persons require liver transplantation (LT). Despite the need, post-LT outcomes are poor in co-infection. We examined predictors of outcomes post-LT. Immunologic biomarkers of immune activation, microbial translocation, and Th1/Th2 skewing were measured pre-LT in participants enrolled in a cohort of HIV infected persons requiring solid organ transplant (HIVTR). Predictive biomarkers were analyzed in Cox-proportional hazards models; multivariate models included known predictors of outcome and biomarkers from univariate analyses. Sixty-nine HIV-HCV co-infected persons with available pre-LT samples were tested: median (IQR) CD4+ T-cell count was 286 (210-429) cells mm-3; 6 (9%) had detectable HIV RNA. Median (IQR) follow-up was 2.1 (0.7-4.0) years, 29 (42%) people died, 35 (51%) had graft loss, 22 (32%) were treated for acute rejection, and 14 (20%) had severe recurrent HCV. In multivariate models, sCD14 levels were significantly lower in persons with graft loss post-LT (HR 0.10 [95%CI 0.02-0.68]). IL-10 levels were higher in persons with rejection (HR 2.10 [95%CI 1.01- 4.34]). No markers predicted severe recurrent HCV. Monocyte activation pre-LT may be mechanistically linked to graft health in HIV-HCV co-infection.

Original languageEnglish (US)
Article numbere0135882
JournalPLoS One
Volume10
Issue number8
DOIs
StatePublished - Aug 27 2015

Fingerprint

liver transplant
Hepatitis C virus
Viruses
Hepacivirus
Liver
Liver Transplantation
HIV
Coinfection
mixed infection
Biomarkers
Transplants
Grafts
biomarkers
Virus Diseases
organ transplantation
Chemical activation
liver diseases
CD4 Lymphocyte Count
T-cells
interleukin-10

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Immunologic predictors of liver transplantation outcomes in HIV-HCV co-infected persons. / Balagopal, Ashwin; Barin, Burc; Quinn, Jeffrey; Rogers, Rodney; Sulkowski, Mark; Stock, Peter G.

In: PLoS One, Vol. 10, No. 8, e0135882, 27.08.2015.

Research output: Contribution to journalArticle

Balagopal, Ashwin ; Barin, Burc ; Quinn, Jeffrey ; Rogers, Rodney ; Sulkowski, Mark ; Stock, Peter G. / Immunologic predictors of liver transplantation outcomes in HIV-HCV co-infected persons. In: PLoS One. 2015 ; Vol. 10, No. 8.
@article{6c5589d855ba438ea34a6bb1bffe731e,
title = "Immunologic predictors of liver transplantation outcomes in HIV-HCV co-infected persons",
abstract = "Liver disease is a leading cause of mortality among HIV-infected persons in the highly active anti-retroviral therapy (HAART) era. Hepatitis C Virus (HCV) co-infection is prevalent in, and worsened by HIV; consequently many co-infected persons require liver transplantation (LT). Despite the need, post-LT outcomes are poor in co-infection. We examined predictors of outcomes post-LT. Immunologic biomarkers of immune activation, microbial translocation, and Th1/Th2 skewing were measured pre-LT in participants enrolled in a cohort of HIV infected persons requiring solid organ transplant (HIVTR). Predictive biomarkers were analyzed in Cox-proportional hazards models; multivariate models included known predictors of outcome and biomarkers from univariate analyses. Sixty-nine HIV-HCV co-infected persons with available pre-LT samples were tested: median (IQR) CD4+ T-cell count was 286 (210-429) cells mm-3; 6 (9{\%}) had detectable HIV RNA. Median (IQR) follow-up was 2.1 (0.7-4.0) years, 29 (42{\%}) people died, 35 (51{\%}) had graft loss, 22 (32{\%}) were treated for acute rejection, and 14 (20{\%}) had severe recurrent HCV. In multivariate models, sCD14 levels were significantly lower in persons with graft loss post-LT (HR 0.10 [95{\%}CI 0.02-0.68]). IL-10 levels were higher in persons with rejection (HR 2.10 [95{\%}CI 1.01- 4.34]). No markers predicted severe recurrent HCV. Monocyte activation pre-LT may be mechanistically linked to graft health in HIV-HCV co-infection.",
author = "Ashwin Balagopal and Burc Barin and Jeffrey Quinn and Rodney Rogers and Mark Sulkowski and Stock, {Peter G.}",
year = "2015",
month = "8",
day = "27",
doi = "10.1371/journal.pone.0135882",
language = "English (US)",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - Immunologic predictors of liver transplantation outcomes in HIV-HCV co-infected persons

AU - Balagopal, Ashwin

AU - Barin, Burc

AU - Quinn, Jeffrey

AU - Rogers, Rodney

AU - Sulkowski, Mark

AU - Stock, Peter G.

PY - 2015/8/27

Y1 - 2015/8/27

N2 - Liver disease is a leading cause of mortality among HIV-infected persons in the highly active anti-retroviral therapy (HAART) era. Hepatitis C Virus (HCV) co-infection is prevalent in, and worsened by HIV; consequently many co-infected persons require liver transplantation (LT). Despite the need, post-LT outcomes are poor in co-infection. We examined predictors of outcomes post-LT. Immunologic biomarkers of immune activation, microbial translocation, and Th1/Th2 skewing were measured pre-LT in participants enrolled in a cohort of HIV infected persons requiring solid organ transplant (HIVTR). Predictive biomarkers were analyzed in Cox-proportional hazards models; multivariate models included known predictors of outcome and biomarkers from univariate analyses. Sixty-nine HIV-HCV co-infected persons with available pre-LT samples were tested: median (IQR) CD4+ T-cell count was 286 (210-429) cells mm-3; 6 (9%) had detectable HIV RNA. Median (IQR) follow-up was 2.1 (0.7-4.0) years, 29 (42%) people died, 35 (51%) had graft loss, 22 (32%) were treated for acute rejection, and 14 (20%) had severe recurrent HCV. In multivariate models, sCD14 levels were significantly lower in persons with graft loss post-LT (HR 0.10 [95%CI 0.02-0.68]). IL-10 levels were higher in persons with rejection (HR 2.10 [95%CI 1.01- 4.34]). No markers predicted severe recurrent HCV. Monocyte activation pre-LT may be mechanistically linked to graft health in HIV-HCV co-infection.

AB - Liver disease is a leading cause of mortality among HIV-infected persons in the highly active anti-retroviral therapy (HAART) era. Hepatitis C Virus (HCV) co-infection is prevalent in, and worsened by HIV; consequently many co-infected persons require liver transplantation (LT). Despite the need, post-LT outcomes are poor in co-infection. We examined predictors of outcomes post-LT. Immunologic biomarkers of immune activation, microbial translocation, and Th1/Th2 skewing were measured pre-LT in participants enrolled in a cohort of HIV infected persons requiring solid organ transplant (HIVTR). Predictive biomarkers were analyzed in Cox-proportional hazards models; multivariate models included known predictors of outcome and biomarkers from univariate analyses. Sixty-nine HIV-HCV co-infected persons with available pre-LT samples were tested: median (IQR) CD4+ T-cell count was 286 (210-429) cells mm-3; 6 (9%) had detectable HIV RNA. Median (IQR) follow-up was 2.1 (0.7-4.0) years, 29 (42%) people died, 35 (51%) had graft loss, 22 (32%) were treated for acute rejection, and 14 (20%) had severe recurrent HCV. In multivariate models, sCD14 levels were significantly lower in persons with graft loss post-LT (HR 0.10 [95%CI 0.02-0.68]). IL-10 levels were higher in persons with rejection (HR 2.10 [95%CI 1.01- 4.34]). No markers predicted severe recurrent HCV. Monocyte activation pre-LT may be mechanistically linked to graft health in HIV-HCV co-infection.

UR - http://www.scopus.com/inward/record.url?scp=84943339146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943339146&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0135882

DO - 10.1371/journal.pone.0135882

M3 - Article

C2 - 26313939

AN - SCOPUS:84943339146

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e0135882

ER -